JP4509113B2 - アフェレーシス装置 - Google Patents

アフェレーシス装置 Download PDF

Info

Publication number
JP4509113B2
JP4509113B2 JP2006525566A JP2006525566A JP4509113B2 JP 4509113 B2 JP4509113 B2 JP 4509113B2 JP 2006525566 A JP2006525566 A JP 2006525566A JP 2006525566 A JP2006525566 A JP 2006525566A JP 4509113 B2 JP4509113 B2 JP 4509113B2
Authority
JP
Japan
Prior art keywords
app
column
binding
peptide
apheresis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006525566A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007504863A5 (enExample
JP2007504863A (ja
Inventor
フランク・マットナー
ヴァルター・シュミット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiris AG
Original Assignee
Affiris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4509113(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Affiris AG filed Critical Affiris AG
Publication of JP2007504863A publication Critical patent/JP2007504863A/ja
Publication of JP2007504863A5 publication Critical patent/JP2007504863A5/ja
Application granted granted Critical
Publication of JP4509113B2 publication Critical patent/JP4509113B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • External Artificial Organs (AREA)
JP2006525566A 2003-09-12 2004-09-13 アフェレーシス装置 Expired - Fee Related JP4509113B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0144403A AT413336B (de) 2003-09-12 2003-09-12 Apherese-vorrichtung
PCT/AT2004/000311 WO2005025651A1 (de) 2003-09-12 2004-09-13 Apherese-vorrichtung

Publications (3)

Publication Number Publication Date
JP2007504863A JP2007504863A (ja) 2007-03-08
JP2007504863A5 JP2007504863A5 (enExample) 2010-03-25
JP4509113B2 true JP4509113B2 (ja) 2010-07-21

Family

ID=34280361

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006525566A Expired - Fee Related JP4509113B2 (ja) 2003-09-12 2004-09-13 アフェレーシス装置

Country Status (15)

Country Link
US (2) US7935252B2 (enExample)
EP (1) EP1663347B1 (enExample)
JP (1) JP4509113B2 (enExample)
CN (1) CN100556472C (enExample)
AT (2) AT413336B (enExample)
AU (1) AU2004271651B2 (enExample)
CA (1) CA2538305C (enExample)
CY (1) CY1107911T1 (enExample)
DE (1) DE502004005851D1 (enExample)
DK (1) DK1663347T3 (enExample)
ES (1) ES2298789T3 (enExample)
HR (1) HRP20080090T3 (enExample)
PL (1) PL1663347T3 (enExample)
PT (1) PT1663347E (enExample)
WO (1) WO2005025651A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5432923B2 (ja) * 2008-12-22 2014-03-05 学校法人藤田学園 Ａβ除去材、Ａβ除去器及びＡβ除去システム

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056318A2 (en) 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT501621A1 (de) * 2005-03-15 2006-10-15 Mattner Frank Dr Zusammensetzungen zur verwendung bei der vorbeugung und behandlung der alzheimer- erkrankung
ES2332846B1 (es) * 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
EP2237804B1 (en) * 2007-12-21 2013-04-10 GE Healthcare Bio-Sciences AB Method for sterilization of chemically activated solid support materials
US20100030196A1 (en) * 2008-07-29 2010-02-04 Medtronic, Inc. Apheresis of a target molecule from cerebrospinal fluid
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
US20110033463A1 (en) * 2009-08-06 2011-02-10 Medtronic, Inc. Apheresis, administration of agent, or combination thereof
EP2497828A1 (en) * 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Use of aptamers in therapy and/or diagnosis of autoimmune diseases
DK2579042T3 (da) 2011-10-04 2014-07-21 Affiris Ag Fremgangsmåde til at påvise Aß-specifikke antistoffer i en biologisk prøve
US9717841B2 (en) 2012-09-11 2017-08-01 Gary L. McNeil Closed-circuit device and methods for isolation, modification, and re-administration of specific constituents from a biological fluid source
AU2015286606A1 (en) * 2014-07-10 2017-01-12 Affiris Ag Substances and methods for the use in prevention and/or treatment in huntington's disease
EP3166966A1 (en) 2014-07-10 2017-05-17 Affiris AG Substances and methods for the use in prevention and/or treatment in huntington's disease
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
GB201904810D0 (en) * 2019-04-05 2019-05-22 Cynapsedx Ltd The treatment of protein aggregation diseases
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57103649A (en) * 1980-12-18 1982-06-28 Asahi Chemical Ind Sterilized gamma-globulin fixing column
JPH06104122B2 (ja) * 1985-09-19 1994-12-21 東レ株式会社 β▲下２▼−ミクログロブリン除去カラム
US5216127A (en) * 1987-11-20 1993-06-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Adsorbent for serum amyloid protein
JPH01171638A (ja) * 1987-12-25 1989-07-06 Kanegafuchi Chem Ind Co Ltd 血清アミロイドａ蛋白用吸着体
DE3853219T2 (de) * 1987-11-20 1995-06-29 Kanegafuchi Chemical Ind Methode zur Entfernung von Serum-Amyloid-Protein.
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
JPH06104122A (ja) 1992-09-21 1994-04-15 Matsushita Electric Ind Co Ltd ロータリートランス
CA2190268C (en) 1994-05-13 2000-01-25 Wolfgang Bohm Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood
DE19549420A1 (de) * 1995-04-27 1997-09-18 Braun Melsungen Ag Verfahren zur simultanen extrakorporalen Elimination von Tumor-Nekrose Faktor alpha (TNF alpha) und bakteriellen Lipopolysacchariden (LPS) aus Vollblut oder/und Blutplasma
US5868936A (en) * 1996-06-20 1999-02-09 Baxter International Inc. Affinity membrane system and method of using same
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
SI1257584T2 (sl) * 2000-02-24 2013-07-31 Washington University St. Louis Humanizirana protitelesa, ki veĹľejo amiloidni peptid beta
TWI238251B (en) * 2000-07-13 2005-08-21 Anawrhta Biotech Co Ltd In-vitro adsorbing device using immunity
WO2003051374A2 (en) * 2001-12-17 2003-06-26 New York State Office Of Mental Health SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
WO2004056318A2 (en) * 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500835B1 (de) * 2004-09-13 2007-12-15 Affiris Forschungs & Entwicklungs Gmbh Cholinestertransport-protein-mimotop als atherosklerose-medikament

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5432923B2 (ja) * 2008-12-22 2014-03-05 学校法人藤田学園 Ａβ除去材、Ａβ除去器及びＡβ除去システム

Also Published As

Publication number Publication date
ATA14442003A (de) 2005-07-15
ATE382383T1 (de) 2008-01-15
HRP20080090T3 (hr) 2008-03-31
CA2538305A1 (en) 2005-03-24
CY1107911T1 (el) 2013-09-04
DK1663347T3 (da) 2008-05-19
CA2538305C (en) 2011-05-24
AU2004271651A1 (en) 2005-03-24
DE502004005851D1 (de) 2008-02-14
HK1096320A1 (zh) 2007-06-01
WO2005025651A1 (de) 2005-03-24
US20070026029A1 (en) 2007-02-01
PL1663347T3 (pl) 2008-06-30
US20110166327A1 (en) 2011-07-07
PT1663347E (pt) 2008-03-28
AU2004271651B2 (en) 2009-08-06
ES2298789T3 (es) 2008-05-16
EP1663347B1 (de) 2008-01-02
US7935252B2 (en) 2011-05-03
CN1867365A (zh) 2006-11-22
EP1663347A1 (de) 2006-06-07
AT413336B (de) 2006-02-15
CN100556472C (zh) 2009-11-04
JP2007504863A (ja) 2007-03-08

Similar Documents

Publication Publication Date Title
JP4509113B2 (ja) アフェレーシス装置
KR101158600B1 (ko) 알츠하이머병을 예방하거나 치료하기 위한 복합 치료법 및이를 위한 키트
US20060030027A1 (en) Capture and removal of biomolecules from body fluids using partial molecular imprints
Rodríguez-Rodríguez et al. Peroxidase sensitive amplifiable probe for molecular magnetic resonance imaging of pulmonary inflammation
US6080404A (en) Materials and methods for removal of substances from fluids
CA3160600A1 (en) Enhancing blood-brain barrier drug transport by targeting endogenous regulators
Spina et al. Chemically modified poly (2‐hydroxyethyl methacrylate) cryogel for the adsorption of heparin
KR101139103B1 (ko) 아페레시스 장치
DK2555790T3 (en) THERAPEUTIC USE OF beta-2-microglobulin
Kawaguchi et al. Novel therapeutic approach for Alzheimer’s disease by removing amyloid β protein from the brain with an extracorporeal removal system
HK1096320B (zh) 分离性输血-设备
CN101720231A (zh) 治疗全身性红斑狼疮的肽和治疗全身性红斑狼疮的方法
Zhen et al. β-amyloid peptide 1–42-conjugated magnetic nanoparticles for the isolation and purification of glycoproteins in egg white
US20150136701A1 (en) Methods and devices for treating a disease state
Chhipa et al. Novel API Coated Catheter Removes Amyloid-β from Plasma of Patients with Alzheimer’s Disease
WO2005025650A1 (de) Apherese-vorrichtung
Bosch et al. Ex vivo biocompatibility of avidin‐agarose: a new device for direct adsorption of biotinylated antibodies from human whole blood
US11186629B2 (en) Treatment method for Cockayne syndrome
US20150291661A1 (en) Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in alzheimer's and vascular dementia
Azhari et al. Specific removal of paraquat by hemoperfusion through antiparaquat conjugated agarose‐polyacrolein microsphere beads
HK1243715B (zh) 来自血液的间-α抑制物蛋白的制备和组合物
JPH0611335B2 (ja) 吸着体および除去装置
BR112012025537B1 (pt) Produto farmacêutico e método de diagnose de uma doença autoimune

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090728

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091028

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091127

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100107

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100330

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100427

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130514

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4509113

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140514

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees